



MEDIGARD LIMITED
Suite 52, Level 5 – HQ, 58 Riverwalk Avenue, Robina QLD 4226 Australia
Telephone +61 7 5578 7822; Fax +61 7 5578 7955
E-mail: office@medigard.com.au www.medigard.com.au
ABN 49 090 003 044

1 February, 2011

Manager of Company Announcements
Australian Stock Exchange Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

No of pages: 1 inclusive

Patent Update

1. Blood Collection Device - Grant of Japanese Patent

Further to our earlier announcements, Medigard Limited (ASX:MGZ) is delighted to announce that its patent application in Japan for its Blood Collection Device (BCD) has now been granted. This provides Medigard with exclusive patent protection in Japan until 21 January, 2025. Medigard has previously received patents for its blood collection device in Australia and in the USA.

“This marks a significant step in the commercialisation of our Blood Collection Device, and represents a further major milestone in the company’s progress” said CEO, Peter Emery. “The Japanese market is one of the largest markets for blood collection devices, and the granting of this patent will facilitate Medigard’s first entry into the Asian market. To have a granted patent in Asia, which is a very large and growing market, not only vindicates our confidence in the product but represents a potential huge step in the marketing of the BCD, both for us and our manufacturing and distribution strategic partners.”

Further patent applications for the Blood Collection Device have been made in Canada and Europe, and Medigard expects the grant of patents in those jurisdictions in the near future.

2. 1mL Auto-retractable Syringe

Medigard has now received the International Preliminary Report on Patentability (IPRP) issued in connection with its International Patent Application (PCT) on its 1mL Auto-retractable Syringe. The IPRP has concluded that all of the claims of the application are novel and inventive. This gives Medigard confidence that the patents, in the jurisdictions where Medigard had applied for a patent, will be granted in due course.

Dr Peter Clark
Executive Director

For further information contact:
Peter Emery, Telephone (07) 5578 7822